In recent years, advancement in genetics has profoundly helped to gain a more
comprehensive molecular, pathogenic, and prognostic picture of pheochromocytomas and …

Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important
modality in the therapeutic armamentarium of advanced, metastatic or inoperable …

Simple Summary Radioligand therapy (RLT) targeting prostate-specific membrane antigen
(PSMA) is an effective antitumor-treatment in metastatic castration-resistant prostate …

In this Review, we discuss clinical developments and controversies in the treatment of
neuroendocrine tumours (NETs) that are relevant for clinicians and clinical researchers. We …

Radioligand therapies have opened new treatment avenues for cancer patients. They offer
precise tumor targeting with a favorable efficacy-to-toxicity profile. Specifically, the kidneys …

A 54-year-old man with multiple endocrine neoplasia type 1 had previous history of
parathyroid surgery and left thyroid lobectomy 5 years earlier, and was referred for recurrent …

This editorial commentary is an expert summary of “Peptide Receptor Radionuclide Therapy
(PRRT),” encompassing the essential fundamentals and salient clinical practice points …

The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine
tumors has been greatly strengthened since the approval of 68Ga-DOTATATE and 177Lu …

The aim was to assess the effect of standard fixed-dose protocol of 177 Lu-DOTATATE
peptide receptor radionuclide therapy (PRRT) in patients with borderline low renal function …